{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-024915","form_type":"8-K","ticker":null,"cik":"0001415684","company_name":"MusclePharm Corp","filed_at":"2023-07-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.857571+00:00","generated_at":"2026-06-13T06:19:57.991580+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MusclePharm terminates CFO Gary Shirshac; names Anthony Todaro interim CFO","bullets":["Gary Shirshac terminated as CFO effective July 10, 2023.","Anthony Todaro appointed as interim CFO as of same date.","Company remains in Chapter 11 bankruptcy (filed Dec. 15, 2022, case 22-14422).","Monthly operating reports from the bankruptcy case attached as exhibits."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-024915","json":"https://secwatch.observer/filing/0001493152-23-024915.json","markdown":"https://secwatch.observer/filing/0001493152-23-024915.md","text":"https://secwatch.observer/filing/0001493152-23-024915.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1415684/000149315223024915/0001493152-23-024915-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1415684/000149315223024915/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T06:19:57.991580+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"da2f9c37c0","claim":"Gary Shirshac was terminated as Chief Financial Officer at MusclePharm Corp.","evidence_excerpt":"Effective as of July 10, 2023, MusclePharm Corporation (the “Company”) terminated Chief Financial Officer, Gary Shirshac.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1415684/000149315223024915/0001493152-23-024915-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"eb6a51d793","claim":"Anthony Todaro was appointed as interim Chief Financial Officer at MusclePharm Corp.","evidence_excerpt":"As of this filing, Anthony Todaro has been named as the Company’s interim Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1415684/000149315223024915/0001493152-23-024915-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}